ppharmПедиатрическая фармакологияPediatric pharmacology1727-57762500-3089Издательство «ПедиатрЪ»10.15690/pf.v11i3.1008ppharm-97Research ArticleРЕДКИЕ БОЛЕЗНИRARE DISEASESПРИМЕНЕНИЕ ТАКРОЛИМУСА У ДЕТЕЙ ПРИ ПЕРЕСАДКЕ ПОЧЕК ОТ ЖИВЫХ РОДСТВЕННЫХ ДОНОРОВUSE OF TACROLIMUS IN CHILDREN FOR TRANSPLANTATION OF KIDNEYS TAKEN FROM LIVE RELATIVE DONORSГоряйновВ. А.GoryainovV. A.

ведущий научный сотрудник отделения трансплантации почки Российского научного центра хирургии им. академика Б.В. Петровского

leading research scientist at the kidney transplantation department of the Petrovskiy Russian scientific center of surgery

vik-kid@mail.ruКаабакМ. М.KaabakM. M.БабенкоН. Н.BabenkoN. N.МорозоваМ. М.MorozovaM. M.ПлатоваЕ. Н.PlatovaE. N.АгурееваЛ. И.AgureevaL. I.ПанинВ. В.PaninV. V.ДымоваО. В.DymovaO. V.Российский научный центр хирургии имени академика Б.В. Петровского, МоскваРоссияPetrovskiy Russian scientific center of surgery, MoscowRussian FederationРоссийский научный центр хирургии имени академика Б.В. Петровского, Москва, Российская ФедерацияРоссияPetrovskiy Russian Scientific Center of Surgery, Moscow, Russian FederationRussian Federation201403062014113Педиатрическая фармакология4852Copyright © Горяйнов В.А., Каабак М.М., Бабенко Н.Н., Морозова М.М., Платова Е.Н., Агуреева Л.И., Панин В.В., Дымова О.В., 20142014Горяйнов В.А., Каабак М.М., Бабенко Н.Н., Морозова М.М., Платова Е.Н., Агуреева Л.И., Панин В.В., Дымова О.В.Goryainov V.A., Kaabak M.M., Babenko N.N., Morozova M.M., Platova E.N., Agureeva L.I., Panin V.V., Dymova O.V.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.pedpharma.ru/jour/article/view/97

The authors present their experience of immunosuppressive therapy with calcineurin blockers in the post-transplantation period (after living-related kidney transplantation). The study was aimed at determining effect of immunosuppressive drug tacrolimus on results of living-related kidney transplantation in children (group 1). The 58 children, who did not receive tacrolimus in the process of the study, constituted the control group (group 2). The following parameters were used to perform comparative analysis: Kaplan-Meier cumulative survivability of recipients and transplants, Cox cumulative hazard level, log-rank test. Moreover, we calculated the rates of transplanted kidney loss and mortality. Results: survivability of transplants and patients was higher in the main group than in the control group (p < 0.05). Conclusions: thus, results of the performed analysis allow claiming that use of tacrolimus for immunosuppressive therapy positively affects results of the living-related kidney allotransplantation in children.

 

аллотрансплантациявыживаемостьтрансплантатиммуносупрессияэффективностьдетиallotransplantationsurvivabilitytransplantimmunosuppressionefficacychildrenReferencesHan D. J., Park J. B. et al. A 39-month follow-up study to evaluate the safety and efficacy in kidney transplant recipients treated with modified-release Tacrolimus (FK-506E)-based immunosuppression regimen. Transplant Proc. 2012; 44 (1): 115–117.Han D. J., Park J. B. et al. A 39-month follow-up study to evaluate the safety and efficacy in kidney transplant recipients treated with modified-release Tacrolimus (FK-506E)-based immunosuppression regimen. Transplant. Proc. 2012; 44 (1): 115–117.Kramer B. K., Charpantier B., Backman L. et al. Tacrolimus once daily (Advagraf) versus twice daily (Prograf) in de novo renal transplantation: a randomized phase III study. Amer J Transplant. 2010; 10 (12): 2632–2643.Kramer B. K., Charpantier B., Backman L. et al. Tacrolimus once daily (Advagraf) versus twice daily (Prograf) in de novo renal transplantation: a randomized phase III study. Amer. J. Transplant. 2010; 10 (12): 2632–2643.Hougardy J. M., Broeders N., Klanda M. et al. Conversion from Prograf to Advagraf among kidney transplant recipients results in sustained decrease in tacrolimus exposure. Transplantation. 2011; 91 (5): 566–569.Hougardy J. M., Broeders N., Klanda M. et al. Conversion from Prograf to Advagraf among kidney transplant recipients results in sustained decrease in tacrolimus exposure. Transplantation. 2011; 91 (5): 566–569.Carcas-Sansuan A. J., Espinosa-Roman L., Almeda-Paulo G. N. et al. Conversion from Prograf to Advagraf in stable paediatric renal transplant patients and 1-year follow-up. Pediatric Nephrology. 2014; 29: 117–123.Carcas-Sansuan A. J., Espinosa-Roman L., Almeda-Paulo G. N. et al. Conversion from Prograf to Advagraf in stable paediatric renal transplant patients and 1-year follow-up. Pediatric Nephrology. 2014; 29: 117–123.Crespo M., Mir M., Marin M., Hurtado S. et al. De novo kidney transplant recipients need higher doses of Advagraf compared with Prograf to get therapeutic levels. Transplant Proc. 2009; 41 (6): 2115–2117.Crespo M., Mir M., Marin M., Hurtado S. et al. De novo kidney transplant recipients need higher doses of Advagraf compared with Prograf to get therapeutic levels. Transplant. Proc. 2009; 41 (6): 2115–2117.

The authors declare that there are no conflicts of interest present.